AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29940782 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant medication (single dose)
Number of subjects: 87
Study 29940870 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatients with unipolar major depression
Number of subjects: 82
Study 29940870 — intervention group
Group type: COMPARATOR
Intervention: Non-depressed controls
Number of subjects: 82
Study 29940894 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 271
Study 29940894 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacing 30 min of sedentary time with 30 min of MVPA
Number of subjects: 271
Study 29940894 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behavior
Number of subjects: 271
Study 29940894 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-intensity activity
Number of subjects: 271
Study 29940894 — intervention group
Group type: EXPERIMENTAL
Intervention: MVPA
Number of subjects: 271
Study 29940894 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacing sedentary time with light-intensity activity
Number of subjects: 271
Study 29940894 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacing light activity with MVPA
Number of subjects: 271
Study 29941012 — intervention group
Group type: EXPERIMENTAL
Intervention: Jugular vein catheterization
Number of subjects: 160
Study 29941012 — intervention group
Group type: COMPARATOR
Intervention: Femoral vein catheterization
Number of subjects: 160
Study 29941024 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard physical education curriculum (60 min/week, low-to-moderate intensity)
Number of subjects: 100
Study 29941024 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity physical education curriculum (HIPE, 60 min/session, 3 times/week, 300-500 kcal/session at 75-85% HRmax)
Number of subjects: 100
Study 29941024 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-to-moderate intensity physical education curriculum (LIPE, 60 min/session, 3 times/week, 300 kcal/session at 55-75% HRmax)
Number of subjects: 100
Study 29941024 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined HIPE and LIPE curriculum (60 min/session, 3 times/week)
Number of subjects: 100
Study 29941047 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen/Esomeprazole (NAP/ESO)
Number of subjects: 46
Study 29941235 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle program
Number of subjects: 779
Study 29941289 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion pancreatectomy
Number of subjects: 0
Study 29941289 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 29941458 — intervention group
Group type: EXPERIMENTAL
Intervention: New risk stratification system
Number of subjects: 0
Study 29941469 — intervention group
Group type: EXPERIMENTAL
Intervention: Siemens-hs-cTnI-Centaur
Number of subjects: 1755
Study 29941469 — intervention group
Group type: COMPARATOR
Intervention: Roche-hs-cTnT-Elecsys
Number of subjects: 1755
Study 29941469 — intervention group
Group type: COMPARATOR
Intervention: Abbott-hs-cTnI-Architect
Number of subjects: 1755
Study 29941496 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0
Study 29941496 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29941707 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic exenteration (PE)
Number of subjects: 38
Study 29942123 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPTURE assessment (5 questions and PEF thresholds)
Number of subjects: 73
Study 29942123 — intervention group
Group type: EXPERIMENTAL
Intervention: mMRC dyspnea scale and CAT™
Number of subjects: 73
Study 29942272 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Technology Application
Number of subjects: 0
Study 29942272 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29942346 — intervention group
Group type: EXPERIMENTAL
Intervention: BE FIT program
Number of subjects: 66
Study 29942346 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 66
Study 29942424 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel Noninvasive Ultrasound Body Sculpting Device
Number of subjects: 0
Study 29942422 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonalcoholic Fatty Liver Disease (NAFLD) prevalence among psoriasis patients
Number of subjects: 0
Study 29942422 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29942590 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health intervention using the Social Pounds Off Digitally (POD) app.
Number of subjects: 0
Study 29942591 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-guided E-Couch social anxiety module
Number of subjects: 0
Study 29942591 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 0
Study 29942666 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX/D/T (FOLFOX plus durvalumab and tremelimumab)
Number of subjects: 48
Study 29942666 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX (standard therapy)
Number of subjects: 48
Study 29943666 — intervention group
Group type: EXPERIMENTAL
Intervention: PVSRIPO (recombinant nonpathogenic polio-rhinovirus chimera)
Number of subjects: 61
Study 29943734 — intervention group
Group type: EXPERIMENTAL
Intervention: hsPDA (hemodynamically significant patent ductus arteriosus)
Number of subjects: 0
Study 29943734 — intervention group
Group type: COMPARATOR
Intervention: Closed ductus arteriosus (DA)
Number of subjects: 0
Study 29944518 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron (IVI) treatment with ferric carboxymaltose (500-1000 mg)
Number of subjects: 1101
Study 29944518 — intervention group
Group type: COMPARATOR
Intervention: No intravenous iron (IVI) treatment
Number of subjects: 1101
Study 29944518 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron (IVI) treatment
Number of subjects: 1101
Study 29944518 — intervention group
Group type: COMPARATOR
Intervention: Intravenous iron (IVI) treatment and no IVI treatment
Number of subjects: 1101
Study 29944518 — intervention group
Group type: COMPARATOR
Intervention: Anemia
Number of subjects: 1101
Study 29944678 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive participants with CD4>500
Number of subjects: 11500
Study 29944678 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive participants with CD4 351-500
Number of subjects: 11500
Study 29944678 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive participants with CD4 ≤350
Number of subjects: 11500
Study 29944678 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-negative participants residing with a CD4>500 HIV-positive person
Number of subjects: 11500
Study 29944678 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-negative participants residing with an HIV-positive person with CD4 351-500
Number of subjects: 11500
Study 29944678 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-negative participants residing with a household member with CD4 ≤350
Number of subjects: 11500
Study 29944678 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive participants in all CD4 categories
Number of subjects: 11500
Study 29944728 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid Capture 2 (HC2; Qiagen)
Number of subjects: 4168
Study 29944728 — intervention group
Group type: EXPERIMENTAL
Intervention: Aptima (Hologic)
Number of subjects: 4168
Study 29944728 — intervention group
Group type: EXPERIMENTAL
Intervention: PreservCyt medium (Hologic) with HC2
Number of subjects: 4168
Study 29944728 — intervention group
Group type: COMPARATOR
Intervention: Aptima or Cobas 4800 (Roche Diagnostics) with PreservCyt
Number of subjects: 4168
Study 29945604 — intervention group
Group type: EXPERIMENTAL
Intervention: School doctors' routine health checks
Number of subjects: 1050
Study 29945604 — intervention group
Group type: COMPARATOR
Intervention: Study questionnaires filled by parents, nurses, and teachers
Number of subjects: 1050
Study 29945630 — intervention group
Group type: EXPERIMENTAL
Intervention: Certified service or hearing dogs
Number of subjects: 55
Study 29945630 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical service dogs
Number of subjects: 55
Study 29945630 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes alert dogs
Number of subjects: 55
Study 29945630 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D
Number of subjects: 55
Study 29945631 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component Sickle Cell Disease Implementation Consortium (SCDIC) interventions
Number of subjects: 0
Study 29945633 — intervention group
Group type: EXPERIMENTAL
Intervention: Lognormal approach for analyzing postpartum blood loss
Number of subjects: 0
Study 29945645 — intervention group
Group type: EXPERIMENTAL
Intervention: Miscarriage between 6 and 8 weeks gestation
Number of subjects: 30166
Study 29945645 — intervention group
Group type: EXPERIMENTAL
Intervention: Miscarriage between 8 and 12 weeks gestation
Number of subjects: 30166
Study 29945645 — intervention group
Group type: EXPERIMENTAL
Intervention: Miscarriage between 12 and 20 weeks gestation
Number of subjects: 30166
Study 29945645 — intervention group
Group type: EXPERIMENTAL
Intervention: Medically terminated pregnancy (MTP) between 6 and 8 weeks gestation
Number of subjects: 30166
Study 29945645 — intervention group
Group type: EXPERIMENTAL
Intervention: Medically terminated pregnancy (MTP) between 8 and 12 weeks gestation
Number of subjects: 30166
Study 29945645 — intervention group
Group type: EXPERIMENTAL
Intervention: Medically terminated pregnancy (MTP) between 12 and 20 weeks gestation
Number of subjects: 30166
Study 29945645 — intervention group
Group type: EXPERIMENTAL
Intervention: Stillbirth rate
Number of subjects: 30166
Study 29945645 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal mortality rate
Number of subjects: 30166
Study 29945645 — intervention group
Group type: EXPERIMENTAL
Intervention: Living infant at 28 days of age
Number of subjects: 30166
Study 29945645 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for miscarriage and MTP
Number of subjects: 30166
Study 29945647 — intervention group
Group type: EXPERIMENTAL
Intervention: Population-based pregnancy outcome registry
Number of subjects: 427111
Study 29945647 — intervention group
Group type: COMPARATOR
Intervention: No prenatal care
Number of subjects: 427111
Study 29945647 — intervention group
Group type: COMPARATOR
Intervention: Zero parity and parity > 3
Number of subjects: 427111
Study 29945647 — intervention group
Group type: COMPARATOR
Intervention: Maternal age < 20 years and age > 35 years
Number of subjects: 427111
Study 29945651 — intervention group
Group type: EXPERIMENTAL
Intervention: Research tests for infection and other conditions, standard autopsy, and minimally invasive tissue sampling conducted on stillbirths and preterm neonates who die ≤ 28 days.
Number of subjects: 0
Study 29945665 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate availability in public facilities
Number of subjects: 88
Study 29945665 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate availability in private facilities
Number of subjects: 88
Study 29945665 — intervention group
Group type: EXPERIMENTAL
Intervention: Usage of magnesium sulphate for severe pre-eclampsia
Number of subjects: 88
Study 29945665 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-usage of magnesium sulphate for eclampsia
Number of subjects: 88
Study 29945665 — intervention group
Group type: EXPERIMENTAL
Intervention: Stock outs of magnesium sulphate
Number of subjects: 88
Study 29945665 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulations of magnesium sulphate
Number of subjects: 88
Study 29945665 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations for improving magnesium sulphate use
Number of subjects: 88
Study 29945738 — intervention group
Group type: COMPARATOR
Intervention: Montelukast (10 mg/day)
Number of subjects: 228
Study 29945738 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg/day) / Levocetirizine (5 mg/day)
Number of subjects: 228
Study 29945859 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) social network during awake craniotomy
Number of subjects: 3
Study 29945861 — intervention group
Group type: EXPERIMENTAL
Intervention: Young with Diabetes app
Number of subjects: 151
Study 29945861 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 151
Study 29945907 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual inspection of pressure-time curve by trained clinicians
Number of subjects: 36
Study 29945907 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual inspection of pressure-time curve to distinguish downward concavity from linear shape
Number of subjects: 36
Study 29945907 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual inspection of pressure-time curve to distinguish upward concavity from linear shape
Number of subjects: 36
Study 29945907 — intervention group
Group type: COMPARATOR
Intervention: Quantitative analysis of SI using specific research software (reference method)
Number of subjects: 36
Study 29946005 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib added to pirfenidone treatment
Number of subjects: 0
Study 29946005 — intervention group
Group type: COMPARATOR
Intervention: Pirfenidone (1602-2403 mg·day)
Number of subjects: 0
Study 29946013 — intervention group
Group type: EXPERIMENTAL
Intervention: Packed red blood cell transfusion
Number of subjects: 413
Study 29946013 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin concentration >10 g/dL
Number of subjects: 413
Study 29946013 — intervention group
Group type: COMPARATOR
Intervention: Anemia after aneurysm securing
Number of subjects: 413
Study 29946013 — intervention group
Group type: COMPARATOR
Intervention: Anemia during delayed cerebral ischemia window
Number of subjects: 413
Study 29946297 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic insufficient sleep (1:2 sleep:wake ratio, 6.67 hours sleep:13.33 hours wake)
Number of subjects: 0
Study 29946297 — intervention group
Group type: COMPARATOR
Intervention: Control (1:2 sleep:wake ratio, 6.67 hours sleep:13.33 hours wake)
Number of subjects: 0
Study 29946480 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot study intervention
Number of subjects: 250
Study 29946480 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary exploratory clinical outcomes
Number of subjects: 250
Study 29946558 — intervention group
Group type: EXPERIMENTAL
Intervention: Multipolar pacing (MPP)
Number of subjects: 24
Study 29946558 — intervention group
Group type: COMPARATOR
Intervention: Best BiV pacing (BestBiV)
Number of subjects: 24
Study 29946558 — intervention group
Group type: COMPARATOR
Intervention: Multisite pacing (MPP and MVP)
Number of subjects: 24
Study 29946558 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisite pacing (MVP)
Number of subjects: 24
Study 29946683 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz
Number of subjects: 694
Study 29946683 — intervention group
Group type: COMPARATOR
Intervention: Nevirapine
Number of subjects: 694
Study 29946946 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA) patients with varying AHI levels
Number of subjects: 101
Study 29946946 — intervention group
Group type: COMPARATOR
Intervention: Healthy older subjects without OSA (AHI < 15)
Number of subjects: 101
Study 29946946 — intervention group
Group type: EXPERIMENTAL
Intervention: Older subjects with incident hypertension
Number of subjects: 101
Study 29947727 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (observational study)
Number of subjects: 129276
Study 29947745 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood sexual abuse
Number of subjects: 421
Study 29947745 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional abuse
Number of subjects: 421
Study 29947745 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional neglect
Number of subjects: 421
Study 29947745 — intervention group
Group type: EXPERIMENTAL
Intervention: Inconsistency experiences
Number of subjects: 421
Study 29947745 — intervention group
Group type: COMPARATOR
Intervention: Physical abuse/neglect
Number of subjects: 421
Study 29947745 — intervention group
Group type: COMPARATOR
Intervention: Violence against the mother
Number of subjects: 421
Study 29947745 — intervention group
Group type: COMPARATOR
Intervention: Drug abuse in the family
Number of subjects: 421
Study 29947745 — intervention group
Group type: COMPARATOR
Intervention: Mentally handicapped family members
Number of subjects: 421
Study 29947745 — intervention group
Group type: COMPARATOR
Intervention: Suicidal intentions in the family
Number of subjects: 421
Study 29947745 — intervention group
Group type: COMPARATOR
Intervention: Family members in prison
Number of subjects: 421
Study 29947766 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometriosis
Number of subjects: 1120
Study 29947766 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1120
Study 29947806 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal serum cobalamin concentration at week 18 of pregnancy
Number of subjects: 114
Study 29947806 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma total homocysteine (tHcy) levels
Number of subjects: 114
Study 29947806 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma methylmalonic acid (MMA) levels
Number of subjects: 114
Study 29947806 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal serum cobalamin concentration <394 pmol/L at week 18
Number of subjects: 114
Study 29947806 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of maternal serum cobalamin concentration with infant serum cobalamin concentration
Number of subjects: 114
Study 29948106 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG PET/CT
Number of subjects: 68
Study 29948106 — intervention group
Group type: EXPERIMENTAL
Intervention: Consecutive PET/CTs
Number of subjects: 68
Study 29948165 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear array ultrasound measurement of LUS-muscular thickness
Number of subjects: 33
Study 29948165 — intervention group
Group type: EXPERIMENTAL
Intervention: Curved array ultrasound measurement of LUS-muscular thickness
Number of subjects: 33
Study 29948165 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative ultrasound measurement of LUS-muscular thickness
Number of subjects: 33
Study 29948233 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment (CBT)
Number of subjects: 81
Study 29948233 — intervention group
Group type: COMPARATOR
Intervention: Educational play group (control)
Number of subjects: 81
Study 29948286 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained atrial fibrillation (AF)
Number of subjects: 1089
Study 29948286 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant heart failure (HF) with sustained AF
Number of subjects: 1089
Study 29948299 — intervention group
Group type: EXPERIMENTAL
Intervention: Giant cavernous carotid aneurysms with lateral mass effect
Number of subjects: 34
Study 29948299 — intervention group
Group type: EXPERIMENTAL
Intervention: Giant cavernous carotid aneurysms with mixed medial/lateral mass effect
Number of subjects: 34
Study 29948299 — intervention group
Group type: EXPERIMENTAL
Intervention: Giant cavernous carotid aneurysms with medial mass effect
Number of subjects: 34
Study 29948299 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of partial thrombosis (PT)
Number of subjects: 34
Study 29948299 — intervention group
Group type: EXPERIMENTAL
Intervention: Aneurysm volume
Number of subjects: 34
Study 29948299 — intervention group
Group type: EXPERIMENTAL
Intervention: Occurrence of PT
Number of subjects: 34
Study 29948299 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient age
Number of subjects: 34
Study 29948356 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonidegib plus docetaxel (fixed dose at 75 mg/m2)
Number of subjects: 0
Study 29948397 — intervention group
Group type: EXPERIMENTAL
Intervention: eSNAP (electronic Social Network Assessment Program)
Number of subjects: 40
Study 29948397 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study 29948566 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily PPI therapy
Number of subjects: 0
Study 29948566 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily PPI therapy
Number of subjects: 0
Study 29948566 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin/NSAID use
Number of subjects: 0
Study 29948566 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoprevention after mucosal ablation
Number of subjects: 0
Study 29948766 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib
Number of subjects: 8
Study 29949102 — intervention group
Group type: EXPERIMENTAL
Intervention: Verinurad 15 mg administered orally under fasted conditions
Number of subjects: 8
Study 29949102 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal renal function)
Number of subjects: 8
Study 29949132 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 or 10 mg BID
Number of subjects: 199
Study 29949132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study 29949132 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 or 10 mg BID in LTE study
Number of subjects: 199
Study 29949718 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-genome sequencing (WGS) in severe COPD patients
Number of subjects: 1794
Study 29949718 — intervention group
Group type: COMPARATOR
Intervention: Control subjects with normal pulmonary function
Number of subjects: 1794
Study 29950123 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous vitamin C (Pascorbin®; Pascoe, Giessen, Germany)
Number of subjects: 71
Study 29950349 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral Poly-ICLC
Number of subjects: 0
Study 29950463 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural corollaries and recovery after ACL injury (no specific intervention mentioned)
Number of subjects: 130
Study 29950463 — intervention group
Group type: EXPERIMENTAL
Intervention: ACL reconstruction (for participants who have surgical treatment)
Number of subjects: 130
Study 29950464 — intervention group
Group type: EXPERIMENTAL
Intervention: Cauterisation
Number of subjects: 0
Study 29950464 — intervention group
Group type: COMPARATOR
Intervention: Fibrin glue
Number of subjects: 0
Study 29950465 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time audio-visual feedback on TSD to caregivers via premounted handhelds and tablets
Number of subjects: 300
Study 29950475 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (add-on treatment to insulin therapy)
Number of subjects: 100